TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps a Buy rating on the shares. The firm updated its model following Q4 beat and raised guidance and sees confident signals on numerous drivers; including EMR integrations, shift to blood-based tests, community uptake, new indications, pharma/ guidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies price target raised to $22 from $21 at BTIG
- 3 ‘Strong Buy’ Stocks to Buy Now, 2/6/2026, According to Top Analysts
- Adaptive Biotechnologies price target raised to $21 from $20 at JPMorgan
- Adaptive Biotechnologies: Sustained MRD Growth, Pricing Power, and Strategic Positioning Support Buy Rating and Premium Valuation
- Adaptive Biotechnologies: Strong MRD Momentum, Enhanced 2026 Outlook, and Clear Path to Profitability Support Buy Rating